Next-Generation Androgen Receptor-Signaling Inhibitors for Prostate Cancer: Considerations for Older Patients
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Geriatrics and Gerontology
Link
http://link.springer.com/content/pdf/10.1007/s40266-020-00809-3.pdf
Reference87 articles.
1. Prostate Cancer: Statistics 2020. Cancer. https://www.cancer.net/cancer-types/prostate-cancer/statistics. Accessed 22 Apr 2020.
2. Boyle HJ, Alibhai S, Decoster L, Efstathiou E, Fizazi K, Mottet N, et al. Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients. Eur J Cancer. 2019;116:116–36.
3. Lichtman SM, Wildiers H, Launay-Vacher V, Steer C, Chatelut E, Aapro M. International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer. 2007;43(1):14–34.
4. Graff JN, Smith MR, Saad F, et al. Age-related efficacy and safety of apalutamide (APA) plus ongoing androgen deprivation therapy (ADT) in subgroups of patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): post hoc analysis of SPARTAN (abstract). J Clin Oncol. 2019;37(15_suppl):5024. https://doi.org/10.1200/JCO.2019.37.15_suppl.5024.
5. Loh KP, Mohile SG, Kessler E, Fung C. Treatment of metastatic prostate cancer in older adults. Curr Oncol Rep. 2016;18(10):63.
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Falls in older adults during treatment for metastatic castration-resistant prostate cancer;Journal of Geriatric Oncology;2024-08
2. Androgen Signaling in Prostate Cancer: When a Friend Turns Foe;Endocrine, Metabolic & Immune Disorders - Drug Targets;2024-05-31
3. Protocol of a randomised, controlled trial comparing immediate curative therapy with conservative treatment in men aged ≥75 years with non‐metastatic high‐risk prostate cancer (SPCG 19/GRand‐P);BJU International;2024-03-12
4. Comparison of standard-dose and reduced-dose treatment of metastatic prostate cancer with enzalutamide, apalutamide or darolutamide: a rapid review;BMJ Oncology;2024-02
5. Real-World Treatment Patterns Among French Patients With Metastatic Castration-Resistant Prostate Cancer Under Abiraterone or Enzalutamide;Clinical Genitourinary Cancer;2023-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3